Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
recWT1-A10+AS01B Immunotherapy After Allo-SCT in Myeloid Malignancies
NCT01819558Phase 2Completed
- Sponsor
- Institut Paoli-Calmettes
- Start
- Mar 2013
- Primary completion
- Mar 2015
- Modality
- Therapeutic Vaccines, Recombinant Protein Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recwt1-A10 + AS01B in acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS), sponsored by Institut Paoli-Calmettes. Primary endpoint: Safety at 30 days. Started Mar 2013; status: completed.
02
Drugs
recwt1-A10 + AS01B
03
Conditions
acute myeloid leukemia (AML)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01819558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01819558.